期刊文献+

PUMA在吉西他滨诱导胰腺癌细胞凋亡过程中的作用 被引量:1

Effect of PUMA in Gemcitabine-induced apoptosis of human pancreatic cancer cell lines
下载PDF
导出
摘要 目的研究吉西他滨体外对人胰腺癌AsPC-1细胞生长的作用机制。方法用脂质体转染法将p53正向凋亡调控因子(PUMA)反义核酸(反义PUMA cDNA)的真核表达载体pcDNA3.1-PUMAAS和空载体pcDNA3.1-导入AsPC-1细胞,G418筛选阳性细胞,获得稳定转染的阳性克隆。将转染载体的AsPC-1阳性克隆细胞和未转染载体的AsPC-1细胞分别暴露于浓度1、5、10和15μmol/ml的吉西他滨中作用72 h。RT-PCR和Western blotting检测不同组细胞经吉西他滨作用72 h后的PUMA表达;MTT检测细胞生长抑制,流式细胞仪(FCM)、Hoechst 33258荧光染色法和TUNEL法检测细胞凋亡。结果吉西他滨促进AsPC-1细胞凋亡,抑制细胞生长,并有明显的剂量依赖性,在细胞凋亡的同时伴有PUMA表达的上调;当细胞转染PUMA反义核酸抑制PUMA表达后,受吉西他滨作用的细胞出现PUMA蛋白表达明显降低,同时伴有细胞凋亡的抑制及细胞的明显增殖。结论吉西他滨促进体外AsPC-1细胞凋亡,并抑制其生长,其诱导凋亡与上调PUMA有关。 Objective To investigate the effect of proliferation and apoptosis in pancreatic cancer patients treated by gemcitabine. Methods pcDNA3.1-PUMAAS and pcDNA3.1- was transfected into AsPC-1 cells by Lipofectamine 2000 methods and stable transfected clony was chosen through G418. AsPC-1 cells were divided into transfected pcDNA3. 1- PUMAAS group, transfected pcDNA3. 1- group and control group without transfection. All AsPC-1 cells in three groups were treated with 10 μl efial concentrations ( 1, 5, 10 and 15 μmol/ml) of gemcitabine. MTT assay was used to observe the inhibitory actions of gemcitabine on AsPC-1 cells. The apoptotic rate was detected by using flow cytometry. The apoptosis was assessed by means of Hoechst 33258 dye staining and TUNEL staining. The expression of PUMA protein was detected by using westem blot and RT-PCR. Results The inhibitory action of cell growth was seen in AsPC-1 control cells and pcDNA3.1- cells dealing with gemcitabine as well as the promoting of apoptosis. Gemcitabine inhibited the proliferation of AsPC-1 cells in a concentration-dependent manner. The apoptosis induced by gemeitabine was accompanied with the upregulation of PUMA. In pcDNA3.1-PUMAAS cells treated with gemcitabine, the apoptosis rate was significantly decreased and the proliferation rate was increased compared with the AsPC-1 control cells and pcDNA3.1- cells. The expression of PUMA was significantly decreased in pcDNA3.1-PUMAAS cells than that of pcDNA3.1- cells. Conclusion Gemcitabine can depress the proliferation of AsPC-1 cells in vitro mainly through the induction of apoptosis and the mechanism is probably related to its effect on the regulation of PUMA.
作者 欧树安 张俊
出处 《山东医药》 CAS 北大核心 2009年第32期13-16,共4页 Shandong Medical Journal
基金 江苏省科学研究基金资助项目(JS2007-021)
关键词 胰腺肿瘤 吉西他滨 细胞凋亡 P53正向凋亡调控因子 pancreatic neoplasms gemcitabine apoptosis p53-upregulated modulator of apoptosis
  • 相关文献

参考文献8

二级参考文献37

  • 1Yu J,Zhang L,Hwang PM,et al.PUMA induces the rapid apoptosis of colorectal cancer cell.Mol Cell,2001,7:673-682.
  • 2Nakano K,Vousden KH.PUMA,a novel proapoptotic gene,is induced by p53.Mol Cell,2001,7:683-694.
  • 3Liu FT,Newland AC,Jia L.Bax conformational change is a crucial step for PUMA mediated apoptosis in human leukemia.Biochem Biophys Res Commun,2003,310:956-962.
  • 4Jeffers JR,Parganas E,Lee Y,et al.PUMA is a essential me diator of p53-dependent and independent apoptotic pathways.Cancer Cell,2003,4:321-328.
  • 5Li CQ,Robles AI,Hanigan CL,et al.Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53.Cancer Res,2004,64:3022-3029.
  • 6Shinagawa Y,Kawamata H,Omotehara F,et al.Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated p53.Int J Oncol,2003,22:383-389.
  • 7Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 2007; 7: 504-521
  • 8Adrian TE. Inhibition of pancreatic cancer cell growth. Cell Mol Life Sci 2007; 64: 2512-2521
  • 9Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007; 11: 981-1011
  • 10Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003; 2: 6

共引文献26

同被引文献4

  • 1Spielmann M, Llombart CA, Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer [J]. Oncology, 2001,60(4) :303-307.
  • 2Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Gemcitabine plus cisplatin (GC): a salvage regimen far ad- vanced breast cancer patients who have failed anthracycline and/or taxane therapy[J]. Gan To Kagaku Ryoho, 2006, 33 (6) : 761-766.
  • 3Heinemann V, Sternmler H J, Wohlrab A, et al. High efficacy of gemcitabine and cisplatin in patients with predominantly an- thracycline and taxane-pretreated metastatic breast cancer[J]. Cancer Chemother Pharmacol, 2006,57 (5) : 640-646.
  • 4Caruba T, Cottu PH, Madelaine-Chambrin I, et al. Gemcit- abine-oxaliplatin combination in heavily pretreated metastatic breast cancer:a pilot study on 43 patients[J]. Breast J,2007, 13(2) : 165-171.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部